Comparative Pharmacology
Head-to-head clinical analysis: THYRO BLOCK versus THYROSHIELD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THYRO BLOCK versus THYROSHIELD.
THYRO-BLOCK vs THYROSHIELD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
THYRO-BLOCK (potassium iodide) inhibits thyroid hormone synthesis and release by blocking the oxidation of iodide to iodine, thereby preventing the incorporation of iodine into thyroglobulin. It also reduces the vascularity of the thyroid gland.
Thyroshield (potassium iodide) acts by supplying excess iodide, which inhibits thyroid hormone synthesis via the Wolff-Chaikoff effect, blocks thyroidal iodide uptake, and reduces thyroid vascularity. It also protects the thyroid from radioactive iodine uptake by saturating iodine transport and organification mechanisms.
Oral, 120 mg every 12 hours (total daily dose 240 mg) starting 24 hours before exposure to radioactive iodine and continuing for 5–10 days as directed.
Intravenous: Loading dose 200 mg, then 50 mg every 6 hours; or continuous infusion: 200 mg bolus then 800 mg over 24 hours. Oral: 50 mg every 6 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 36 hours (range 24-48 hours) in euthyroid patients; prolonged in hyperthyroid patients due to increased thyroid hormone binding and reduced clearance.
Terminal elimination half-life is 12-24 hours; clinical effect persists 24-36 hours after single dose.
Primarily renal excretion of unchanged drug (80-90% of absorbed dose) via glomerular filtration; minimal biliary/fecal elimination (<5%).
Primarily renal (90-95% unchanged), minor biliary/fecal (5-10%).
Category C
Category C
Antithyroid Agent
Antithyroid Agent